The Council to Advance Human Health (CAHH) was developed as a catalyst for a focused model of translation, providing small targeted grants for investigators to develop promising projects towards an exit. Eligible investigators are invited to present their projects to obtain funding up to $75,000.
Some spin-outs from CAHH include:
Convelo Therapeutics, Inc.
Read about Convelo in The Daily:
Haima Therapeutics
Read about Haima in the press:
Luminary Therapeutics, Inc.
Read about Luminary in The Daily:
Mosaic Immunoengineering, Inc.
Read about Mosaic in the press:
NervGen Pharma
Read about NervGen in The Daily:
Rodeo Therapeutics, Inc.
Read more about Rodeo in the press:
Q2 Pharma
Read about Q2 in The Daily:
Tevard Biosciences
Read about Tevard in The Daily: